NorthWest Biotherapeutics Inc (NWBO)

[learningcurve2020]

In laboratory studies, CAR and TCR T cells modified to express the cytokines IL-15 and IL-21 on their surface killed far more cancer cells than T cells carrying just one of these cytokines or neither of them. Previous research has found that treating patients with large amounts of cytokines caused severe, potentially fatal, side effects. The new approach aims to deliver this cytokine boost in a much more targeted way.

https://www.nih.gov/news-events/news-releases/nih-researchers-develop-approach-could-help-supercharge-t-cell-therapies-against-solid-tumors

>>We’ve already seen the benefit of [CAR T-cell therapy] in [patients with] B-cell malignancies, but we're starting to [explore CAR T-cell therapy] in lots of solid tumors. We will solve those engineering challenges, and it will come to solid tumors,” Leick said.

>>Investigators at Stanford have recently been using CAR T-cell therapy for a pediatric brain tumor called diffuse intrinsic pontine glioma. They infuse [the treatment] directly into the brain, and they've seen some miraculous results. [CAR T-cell therapy for patients with solid tumors] is coming, and I think it's going to work in those diseases. However, it is just going to take time, and lots of people are working on it.

https://www.onclive.com/view/research-remains-focused-on-bringing-car-t-cell-therapy-to-solid-tumors